Litigation Details for Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (D. Del. 2017)
✉ Email this page to a colleague
Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (D. Del. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-04-05 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Parties | AUROBINDO PHARMA USA INC. | ||
| Patents | 6,017,927; 6,967,208; 9,326,945 | ||
| Attorneys | Arthur G. Connolly , III | ||
| Firms | Farnan LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-06-20 | 536 | Motion to Strike | MacMillan relating to infringement of U.S. Patent No. 6,967,208, Claim 104 - filed by Sigmapharm Laboratories… 5 April 2017 1:17-cv-00374 830 Patent None District Court, D. Delaware | External link to document |
| 2019-06-20 | 537 | Letter | MacMillan relating to infringement of U.S. Patent No. 6,967,208, Claim 104. (Attachments: # 1 Exhibit 1-… 5 April 2017 1:17-cv-00374 830 Patent None District Court, D. Delaware | External link to document |
| 2019-07-01 | 545 | Letter | MacMillan relating to infringement of U.S. Patent No. 6,967,208, Claim 104. (Attachments: # 1 Exhibit A,… 5 April 2017 1:17-cv-00374 830 Patent None District Court, D. Delaware | External link to document |
| 2019-12-20 | 684 | POST Trial Brief | Description ’208 Patent U.S. Patent No. 6,967,208 (JTX-1) ’945 Patent U.S. Patent No. 9,326,945…and Drug Administration Patents-in-Suit The ’208 Patent and ’945 Patent BMS Bristol-Myers…Claims For the ’208 Patent, claims 13 and 104. For the ’945 Patent, claims 21 and 22.…challenged the patents protecting Plaintiffs’ novel, blockbuster anticoagulant, Eliquis®. U.S. Patent No. 6,967,208… Eliquis®, and U.S. Patent No. 9,326,945 (the “’945 Patent”) covers certain compositions containing apixaban | External link to document |
| 2019-12-20 | 685 | Proposed Findings of Fact | Description ’208 Patent U.S. Patent No. 6,967,208 (JTX-1) ’945 Patent U.S. Patent No. 9,326,945… These consolidated cases concern U.S. Patent Nos. 6,967,208 and 9,326,945, both of which are listed…Claims For the ’208 Patent, claims 13 and 104. For the ’945 Patent, claims 21 and 22.… 4. BMS owns the ’208 Patent. UF ¶ 13. The ’208 Patent’s priority date is no later than …BMS and Pfizer jointly own the ’945 Patent. UF ¶ 26. The ’945 Patent’s priority date is no later than | External link to document |
| 2019-12-20 | 686 | POST Trial Brief | Description ’208 Patent U.S. Patent No. 6,967,208 (JTX-1) ’945 Patent U.S. Patent No. 9,326,945…challenged the patents protecting Plaintiffs’ novel, blockbuster anticoagulant, Eliquis®. U.S. Patent No. 6,967,208… Eliquis®, and U.S. Patent No. 9,326,945 (the “’945 Patent”) covers certain compositions containing apixaban…paragraph IV certification for the ’945 Patent but not the ’208 Patent, the only asserted claims against …Statement of Facts A. ’945 Patent The ’945 Patent is titled “Apixaban Formulations” and | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
